BioSpace News Archive

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the completion of the first successful adult human heart transplants from DCD (donation after circulatory death) donors in the United States at Duke University Hospital and Massachusetts General Hospital

Today, Sun Nuclear Corporation released the complete program for the 12th QA & Dosimetry Symposium (QADS), held in Orlando, Florida, February 21-22, 2020.

T-Systems North America (TSNA) and Hitachi Vantara today announced a collaboration to develop new Hitachi Vantara-powered managed services.

Ichnos Sciences Inc. is pleased to announce two important additions to its leadership team. Beginning December 3, 2019, Patrick E. Flanigan III assumed the role of Chief Financial Officer, and effective January 7, 2020 Martin L. Wilson will start as General Counsel (GC).

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including leukemia, prostate and colorectal, today announced new in-vitro and in-vivo data suggesting that onvansertib may provide a new therapeutic option for patients who develop resistance to frontline treatment with venetoclax.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will present at the 12th Annual LD Micro Main Event on Wednesday December 11, 2019 at 11:40 AM PT.

Deloitte and Tisch MS Research Center of New York (Tisch MSRCNY) are using data science, artificial intelligence (AI) and machine learning in a multiphase research project to find patterns that may relate to the cause of multiple sclerosis (MS).

Research Presented Alongside MMRF and HUMC Evaluates Opportunity for RWE to Study Patient Treatment & Outcomes in Routine Cancer Care

Organizations will use next-generation costing system to help executives, analysts and physicians understand and evaluate the true cost of patient care

OptiScan Biomedical Corporation, a developer of an innovative continuous monitoring system for use in the surgical intensive care unit (SICU), today announced the online publication of two peer-reviewed papers highlighting key benefits delivered by the company’s OptiScanner continuous monitoring platform for intensive care units.